Home Tags Fast Track Designation

Tag: Fast Track Designation

FDA Grants Fast Track Designation to DB-1303 for the Treatment of...

ADC Review | Editorial Team
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to DB-1303 a novel antibody-drug conjugates for the treatment of patients with advanced, recurrent or metastatic endometrial carcinoma with HER2 over-expression who have progressed on or after standard systemic treatment.

ESMO 2020: XMT-1536 Shows 34% ORR in Phase I Expansion Study...

ADC Review | Editorial Team
Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536...
Featured image: An aerial view of the Yangtze River Delta/Shanghai in the southern Jiangsu province and northern Zhejiang province. Photo Courtecy: 2015 - 2020 © VCG/Gettyimages. Used with permission.

Everest Medicines to Initiate a Registration Study in China for Sacituzumab...

ADC Review | Editorial Team
China-based Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative products, address critical unmet medical needs for patients in Greater China and...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X